Asymmetric Investing by Travis Hoium on $HIMS

Asymmetric Investing by Travis Hoium has discussed $HIMS in 5 videos since 2026-08-19. The latest, on 2026-11-10, was bullish.

2026-11-10Bullish
“Hims & Hers Collapses 30% In a Week”
AI summary · HIMS fell 18% after a disappointing quarter: subscribers fell about 100,000 QoQ, gross margin dropped from 83% to 57% on branded GLP-1 mix, Q4 revenue is guided slightly down and full-year adjusted EBIT guidance was cut. The speaker is not selling and still calls HIMS a great company to own over 5-10 years, based on its higher-priced subscription, TRT and peptide strategy and Costco-like health-subscription model, with management betting on Q1 2027; short-term subscriber growth and competition leave questions, and next quarter's guidance is important.

Shares of his and hers are down 18% in late trading on Tuesday after their company reported earnings on Monday. The investors did not like what they heard from the earnings report.

In a lot of ways, the report was really disappointing. The number of subscribers was down quarter over quarter. Gross margins continued to be under pressure. And management said that they were actually not spending as much to bring in those new customers. That's why growth really slowed.

2026-11-02Bullish
“Hims & Hers: The 10x Stock You Can't Ignore”
AI summary · HIMS is highly undervalued: it leads a huge US pharma market with 51% observed sales share, is expanding products and internationally, and its peptides could become over a billion dollars by end-2027. Revenue is about $2.6 billion, management guides 50% annual growth in 2H 2026, and peptides could lift revenue to $5-6 billion in a few years; near 1x price-to-sales, that growth deserves a higher multiple. Risks include management stretching across markets, though he backs the team.

In my opinion, one of the companies that has huge opportunities for investors is Hims& Hers. This company is trying to radically change one of the largest industries in the world, namely the medical industry and the pharmaceutical industry.

The pharmaceutical industry is worth about $400 billion in the United States alone. From what I see now, HimsandHers has a market capitalization of only about $6.4 billion. This is a company whose value could increase not just 10 times, but potentially 100 times in the next 10 or 20 years.

2026-10-09Bullish
Why I'm Betting Big on These 5 Growth Stocks
Subscribe or start a trial to unlock this step
2026-09-01Bullish
The Hims & Hers Australia Strategy: Why It Matters for Investors
Subscribe or start a trial to unlock this step
2026-08-19Bullish
4 Incredible Stocks I Love Today
Subscribe or start a trial to unlock this step
3 earlier entries need a subscription
The latest 2 are free to read. Earlier entries keep their date and direction; the text unlocks with a subscription.
Subscribe to read all 3 earlier takes